William Haning to Adult
This is a "connection" page, showing publications William Haning has written about Adult.
Connection Strength
0.196
-
Nakama H, Chang L, Cloak C, Jiang C, Alicata D, Haning W. Association between psychiatric symptoms and craving in methamphetamine users. Am J Addict. 2008 Sep-Oct; 17(5):441-6.
Score: 0.028
-
Haning W, Goebert D. Electrocardiographic abnormalities in methamphetamine abusers. Addiction. 2007 Apr; 102 Suppl 1:70-5.
Score: 0.026
-
Baker FM, Haning WF. Substance abuse and dependence in a public hospital: Hawaii. Hawaii Med J. 2001 Feb; 60(2):35-8.
Score: 0.017
-
Anderson AL, Li SH, Markova D, Holmes TH, Chiang N, Kahn R, Campbell J, Dickerson DL, Galloway GP, Haning W, Roache JD, Stock C, Elkashef AM. Bupropion for the treatment of methamphetamine dependence in non-daily users: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2015 May 01; 150:170-4.
Score: 0.011
-
Adams D, Ditzler T, Haning WF. Primary caffeine dependence: a case report. Hawaii Med J. 1993 Jul; 52(7):190-1, 194.
Score: 0.010
-
Liles BD, Newman E, Lagasse LL, Derauf C, Shah R, Smith LM, Arria AM, Huestis MA, Haning W, Strauss A, Dellagrotta S, Dansereau LM, Neal C, Lester BM. Perceived child behavior problems, parenting stress, and maternal depressive symptoms among prenatal methamphetamine users. Child Psychiatry Hum Dev. 2012 Dec; 43(6):943-57.
Score: 0.010
-
Ma JZ, Johnson BA, Yu E, Weiss D, McSherry F, Saadvandi J, Iturriaga E, Ait-Daoud N, Rawson RA, Hrymoc M, Campbell J, Gorodetzky C, Haning W, Carlton B, Mawhinney J, Weis D, McCann M, Pham T, Stock C, Dickinson R, Elkashef A, Li MD. Fine-grain analysis of the treatment effect of topiramate on methamphetamine addiction with latent variable analysis. Drug Alcohol Depend. 2013 Jun 01; 130(1-3):45-51.
Score: 0.010
-
Smith LM, Paz MS, LaGasse LL, Derauf C, Newman E, Shah R, Arria A, Huestis MA, Haning W, Strauss A, Della Grotta S, Dansereau LM, Neal C, Lester BM. Maternal depression and prenatal exposure to methamphetamine: neurodevelopmental findings from the infant development, environment, and lifestyle (ideal) study. Depress Anxiety. 2012 Jun; 29(6):515-22.
Score: 0.009
-
Shah R, Diaz SD, Arria A, LaGasse LL, Derauf C, Newman E, Smith LM, Huestis MA, Haning W, Strauss A, Della Grotta S, Dansereau LM, Roberts MB, Neal C, Lester BM. Prenatal methamphetamine exposure and short-term maternal and infant medical outcomes. Am J Perinatol. 2012 May; 29(5):391-400.
Score: 0.009
-
Elkashef A, Kahn R, Yu E, Iturriaga E, Li SH, Anderson A, Chiang N, Ait-Daoud N, Weiss D, McSherry F, Serpi T, Rawson R, Hrymoc M, Weis D, McCann M, Pham T, Stock C, Dickinson R, Campbell J, Gorodetzky C, Haning W, Carlton B, Mawhinney J, Li MD, Johnson BA. Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial. Addiction. 2012 Jul; 107(7):1297-306.
Score: 0.009
-
Anderson AL, Li SH, Biswas K, McSherry F, Holmes T, Iturriaga E, Kahn R, Chiang N, Beresford T, Campbell J, Haning W, Mawhinney J, McCann M, Rawson R, Stock C, Weis D, Yu E, Elkashef AM. Modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2012 Jan 01; 120(1-3):135-41.
Score: 0.009
-
Zabaneh R, Smith LM, LaGasse LL, Derauf C, Newman E, Shah R, Arria A, Huestis M, Haning W, Strauss A, Della Grotta S, Dansereau LM, Lin H, Neal C, Lester BM. The effects of prenatal methamphetamine exposure on childhood growth patterns from birth to 3 years of age. Am J Perinatol. 2012 Mar; 29(3):203-10.
Score: 0.009
-
Gray TR, LaGasse LL, Smith LM, Derauf C, Grant P, Shah R, Arria AM, Della Grotta SA, Strauss A, Haning WF, Lester BM, Huestis MA. Identification of prenatal amphetamines exposure by maternal interview and meconium toxicology in the Infant Development, Environment and Lifestyle (IDEAL) study. Ther Drug Monit. 2009 Dec; 31(6):769-75.
Score: 0.008
-
Gray TR, Kelly T, LaGasse LL, Smith LM, Derauf C, Haning W, Grant P, Shah R, Arria A, Strauss A, Lester BM, Huestis MA. Novel biomarkers of prenatal methamphetamine exposure in human meconium. Ther Drug Monit. 2009 Feb; 31(1):70-5.
Score: 0.007
-
Elkashef AM, Rawson RA, Anderson AL, Li SH, Holmes T, Smith EV, Chiang N, Kahn R, Vocci F, Ling W, Pearce VJ, McCann M, Campbell J, Gorodetzky C, Haning W, Carlton B, Mawhinney J, Weis D. Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology. 2008 Apr; 33(5):1162-70.
Score: 0.007
-
Elkashef A, Rawson RA, Smith E, Pearce V, Flammino F, Campbell J, Donovick R, Gorodetzky C, Haning W, Mawhinney J, McCann M, Weis D, Williams L, Ling W, Vocci F. The NIDA Methamphetamine Clinical Trials Group: a strategy to increase clinical trials research capacity. Addiction. 2007 Apr; 102 Suppl 1:107-13.
Score: 0.006
-
Smith LM, LaGasse LL, Derauf C, Grant P, Shah R, Arria A, Huestis M, Haning W, Strauss A, Della Grotta S, Liu J, Lester BM. The infant development, environment, and lifestyle study: effects of prenatal methamphetamine exposure, polydrug exposure, and poverty on intrauterine growth. Pediatrics. 2006 Sep; 118(3):1149-56.
Score: 0.006
-
Arria AM, Derauf C, Lagasse LL, Grant P, Shah R, Smith L, Haning W, Huestis M, Strauss A, Della Grotta S, Liu J, Lester B. Methamphetamine and other substance use during pregnancy: preliminary estimates from the Infant Development, Environment, and Lifestyle (IDEAL) study. Matern Child Health J. 2006 May; 10(3):293-302.
Score: 0.006